Jane Street Group LLC purchased a new stake in Inhibrx, Inc. (NASDAQ:INBX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 88,419 shares of the company's stock, valued at approximately $1,362,000. Jane Street Group LLC owned approximately 0.61% of Inhibrx as of its most recent filing with the SEC.
Several other hedge funds have also recently modified their holdings of INBX. Castalian Partners LLC purchased a new stake in shares of Inhibrx during the 4th quarter worth $2,950,000. Schonfeld Strategic Advisors LLC purchased a new position in Inhibrx in the fourth quarter valued at about $2,220,000. Northern Trust Corp bought a new position in Inhibrx in the fourth quarter worth about $1,788,000. Birchview Capital LP purchased a new stake in shares of Inhibrx during the fourth quarter valued at about $494,000. Finally, Boothbay Fund Management LLC purchased a new stake in shares of Inhibrx during the fourth quarter valued at about $435,000. Hedge funds and other institutional investors own 82.46% of the company's stock.
Inhibrx Price Performance
NASDAQ INBX traded up $0.32 on Friday, hitting $12.86. The stock had a trading volume of 73,671 shares, compared to its average volume of 156,748. The business's fifty day moving average price is $12.50 and its 200 day moving average price is $13.53. The stock has a market cap of $186.16 million and a price-to-earnings ratio of 0.11. Inhibrx, Inc. has a 52-week low of $10.80 and a 52-week high of $34.58.
Inhibrx (NASDAQ:INBX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($2.80) earnings per share for the quarter, missing analysts' consensus estimates of ($2.55) by ($0.25). As a group, sell-side analysts anticipate that Inhibrx, Inc. will post 104.88 EPS for the current year.
Analyst Ratings Changes
Separately, JMP Securities reaffirmed a "market perform" rating on shares of Inhibrx in a research report on Thursday, May 15th.
Check Out Our Latest Report on Inhibrx
About Inhibrx
(
Free Report)
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
Featured Stories
Before you consider Inhibrx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibrx wasn't on the list.
While Inhibrx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
